Abstract
OBJECTIVES: To investigate the effects of percutaneous vertebroplasty with high viscosity bone cement on pain and the levels of bone specific alkaline phosphatase (BALP), Type-I collagen cross-linked telopeptide (CTX) and serum osteocalcin (BGP) in patients with osteoporotic vertebral compression fractures. METHODS: The medical records of patients with osteoporotic vertebral compression fractures treated in our hospital from February 2020 to February 2021 were selected after retrospective analysis. Patients (43) who received low viscosity bone cement percutaneous vertebroplasty comprised Group-I, and patients (56) who received high viscosity bone cement percutaneous vertebroplasty, comprised Group-II of the study. The occurrence of bone cement leakage, pain (VAS scores), BALP, CTX and BGP were compared and analyzed between the two groups. RESULTS: The incidence of bone cement leakage in Group-II was 16.28%, lower than 3.57% in Group-I (P<0.05). The visual analogue scale (VAS) scores of patients in Group-II were lower than those in Group-I at one and three months after the surgery (P<0.05). The levels of BALP and BGP in Group-II were higher than those in Group-I three months after the surgery (P<0.05), and CTX was lower than those in Group-I (P<0.05). CONCLUSIONS: Percutaneous vertebroplasty with high viscosity bone cement in the treatment of osteoporotic vertebral compression fractures can reduce the incidence of bone cement leakage and help to further reduce pain and improve bone metabolism.